Chemed Earnings Call Transcripts
Fiscal Year 2026
-
Admissions and census are growing ahead of expectations, driven by a balanced mix of hospital and non-hospital sources and rapid ramp-up in new Florida markets. CAP mitigation strategies are effective, with new inpatient units and labor expansion supporting future growth. Regulatory scrutiny is welcomed, with a focus on targeted anti-fraud efforts.
-
Census and margin outlooks were raised for the hospice segment, supported by improved referral management and regulatory changes. Expansion continues via de novo growth and selective acquisitions, while digital marketing and operational efficiencies drive recovery in the non-healthcare segment.
-
VITAS delivered strong Q1 2026 results, raising full-year guidance for ADC, revenue, and EPS, while Roto-Rooter showed early signs of recovery despite higher marketing costs and weather disruptions. Franchise acquisitions and improved collections supported growth.
-
Management expressed confidence in VITAS's growth and margin outlook, driven by strong Florida performance and new market entries, while Roto-Rooter guidance remains conservative amid ongoing marketing and collection challenges. Strategic alternatives for Roto-Rooter will be considered if recovery stalls in 2026.
Fiscal Year 2025
-
Fourth quarter 2025 results missed expectations due to margin pressure at both subsidiaries, but operational changes and market adjustments are expected to drive improved revenue and profitability in 2026, especially in the second half. VITAS and Roto-Rooter both face transitional challenges but maintain a positive long-term outlook.
-
Both business segments are rebounding from pandemic and competitive disruptions, with VITAS resolving a one-time Medicare cap issue and Roto-Rooter stabilizing as private equity competition wanes. Strategic focus includes commercial expansion, operational discipline, and maintaining flexibility for future acquisitions or divestitures.
-
Q3 2025 results were in line with expectations, with VITAS mitigating Medicare cap risks and Roto-Rooter showing early signs of stabilization. Management reaffirmed full-year guidance and expects seasonal margin improvements in Q4, with both segments targeting higher growth and margins in 2026.
-
Second quarter 2025 results were below expectations, with VITAS and Roto-Rooter both facing margin pressures from Medicare cap limitations and higher costs. Guidance for 2025 was lowered, but management remains confident in long-term growth, supported by patient mix adjustments and new market entries.
-
Medicare cap management remains robust, with analytics and strategy adjustments supporting sustainable growth. Expansion through targeted acquisitions, especially in Florida, is underway, while Roto-Rooter maintains minimal tariff exposure and pursues growth via commercial focus and digital innovation.
-
VITAS delivered strong Q1 2025 growth with admissions up 7.3% and revenue up 15.1% year-over-year, aided by the Covenant Health acquisition. Roto-Rooter saw modest revenue growth but lower margins due to pricing strategies. Cash flow was impacted by timing of Medicare receivable recovery and PIP payment.
-
Hospice operations are performing in line with guidance, driven by demographic trends and policy support, while new Florida locations ramp up quickly but will impact earnings more in 2026. Roto-Rooter is recovering from sales challenges through targeted management actions, with commercial business leading growth. Capital deployment remains focused on acquisitions and buybacks.
-
The conference highlighted strong long-term growth in both healthcare and plumbing segments, with VITAS showing accelerated patient volume and financial performance. Expansion through acquisitions and organic growth, especially in CON states, is a priority, while regulatory and industry trends are closely monitored.
Fiscal Year 2024
-
VITAS posted strong Q4 growth, driven by the Covenant Health acquisition and robust admissions, while Roto-Rooter saw a revenue decline but exceeded internal expectations. 2025 guidance projects continued growth for both segments, with VITAS moderating margins due to Medicare cap management.
-
Organic hospice census growth is expected to remain strong, supported by demographic trends and operational improvements, with stable margins projected for 2025. M&A and de novo expansion will continue, while Roto-Rooter anticipates modest growth and stable margins as commercial initiatives gain traction.
-
Two leading service businesses are driving growth, with VITAS outperforming expectations and Roto-Rooter addressing post-pandemic challenges. Strategic acquisitions, operational improvements, and a strong balance sheet support continued expansion and shareholder returns.
-
VITAS delivered strong growth in admissions and revenue, aided by the Covenant Health acquisition, while Roto-Rooter faced revenue and margin declines due to industry softness and marketing transition costs. Full-year EPS guidance was lowered but still projects double-digit growth over 2023.
-
VITAS delivered robust growth in admissions and revenue, aided by the Covenant Health acquisition, while Roto-Rooter faced revenue declines due to lower demand and increased competition. Management raised 2024 EPS guidance and remains optimistic about VITAS's outlook, with targeted initiatives underway to improve Roto-Rooter's performance.
-
The conference highlighted strong post-pandemic growth in hospice, driven by robust demand, effective recruitment, and a mission-driven culture. The enterprise anticipates high single-digit revenue and 10% EPS growth, with a strong balance sheet supporting active M&A and expansion plans.